This site is intended for health professionals only

Thursday 22 August 2019
Share |

Latest News

Dupilumab reaches primary and secondary endpoints in paediatric trial

Thursday 8th August 2019
A pivotal Phase III trial evaluating Dupixent® (dupilumab) in severe atopic dermatitis in children has met its primary and secondary endpoints. 
The topline data show that for children with severe atopic dermatitis (covering nearly 60% of their skin surface on average), adding Dupixent to standard-of-care topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching and health-...
Sun, 16 Jun 2019
Study also reveals venous thromboembolism and epilepsy as potential novel comorbidities
Sat, 15 Jun 2019
Initial pilot data support the use of new neurostimulation treatment in a larger study in patients who have failed current standard of care
Fri, 14 Jun 2019
In the European Union alone, an extra one million employees could be in work each day if early interventions were more widely accessible for people with rheumatic and musculoskeletal diseases (RMDs)
Fri, 14 Jun 2019
Over half of patients and rheumatologists report diagnosis within six weeks as the most problematic standard of care
Fri, 14 Jun 2019
Huge impact of pain and sleep on mental health raises questions about the level of care offered to patients
Thu, 13 Jun 2019
Pixantrone has been available to patients since 2012 following a conditional approval in Europe
Thu, 13 Jun 2019
Study reports no vaccine infections in children given live-attenuated booster vaccine while on immune suppressing therapies